We recently published a list of Billionaire George Soros’ 10 Small-Cap Stocks with Huge Upside Potential. In this article, we are going to take a look at where Sarepta Therapeutics, Inc.

It's been nearly two years since Elevidys, a gene therapy for Duchenne MD developed by Sarepta Therapeutics, was approved by ...

John Brandsema, MD, a pediatric neurologist at Children’s Hospital of Philadelphia, speaks with Healio about the latest ...

Here are the most important news items that investors need to start their trading day.

We recently published a list of the 11 Most Promising Long-Term Stocks According to Analysts. In this article, we are going ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") for ...

Piper Sandler lowered the firm’s price target on Sarepta (SRPT) to $110 from $182 and keeps an Overweight rating on the shares. The firm is ...

BofA lowered the firm’s price target on Sarepta (SRPT) to $157 from $179 and keeps a Buy rating on the shares. The firm updated models in smid-cap biotech as part of a Q1 earnings preview.Stay Ahead ...

Multidisciplinary coordination across prescribing teams, nursing, laboratory medicine, finance, and infusion centers is crucial for gene therapy delivery in Duchenne muscular dystrophy (DMD).

Marcos Reyes and Valeria Martínez are in a tough spot, unsure which of their twins should receive the treatment they ...

U.K. regulators cleared a multiple myeloma drug GSK withdrew from market three years ago. Elsewhere, an investment firm pressed Elevation Oncology to liquidate and the FDA relaxed risk monitoring ...

Just a few weeks after closing a $155 million series B, RNA editing biotech AIRNA is bringing an experienced gene therapy ...